A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis

NCT04152226 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Tinea Pedis

Interventions

DRUG: Janthinobacterium lividum

Sponsor

DermBiont, Inc.